Class IIOngoingD-0119-2026
Drug recall · November 5, 2025
Semaglutide Injection recall
Why: Lack of Assurance of Sterility
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Semaglutide Injection, 5 mg/2 mL (2.5 mg/mL), 2mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-02
- Lots / codes
Lot PRORX052125-4
- Quantity
- 2,805 vials
- Company
- ProRx LLC, Exton, PA
- Distribution
- TX and UT
- Initiated
- October 15, 2025 · Voluntary: Firm initiated
- Classified
- October 27, 2025
- Reported
- November 5, 2025
- How notified
- Letter
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Class IIOngoingNov 5, 2025Semaglutide InjectionProRx LLC · D-0114-2026Class IIOngoingNov 5, 2025Semaglutide InjectionProRx LLC · D-0115-2026Class IIOngoingNov 5, 2025Semaglutide InjectionProRx LLC · D-0116-2026Class IIOngoingNov 5, 2025Semaglutide InjectionProRx LLC · D-0117-2026Class IIOngoingNov 5, 2025Semaglutide InjectionProRx LLC · D-0118-2026Class IIOngoingNov 5, 2025Tirzepatide InjectionProRx LLC · D-0120-2026
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.